ABMT.US Advanced Biomedical Technologies Inc
- Market cap
- USD 35.5K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Oct 2023.
Is ABMT.US undervalued?
Graham numberThe Graham number of Advanced Biomedical Technologies Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Advanced Biomedical Technologies Inc fundamental analysis
No fundamental analysis for Advanced Biomedical Technologies Inc yet.
Advanced Biomedical Technologies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Advanced Biomedical Technologies Inc
Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Min…
Full company profileAdvanced Biomedical Technologies Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 4 quarters up to Oct 31, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Advanced Biomedical Technologies Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.7K | 124K | 171K | 271K | - |
| Gross Profit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.06K | 71.8K | 93.3K | 222K | - |
| Operating Income | -719K | -618K | -605K | -461K | -404K | -634K | -605K | -447K | -395K | -180K | - |
| EBITDA | -693K | -591K | -575K | -446K | -420K | -636K | -601K | -283K | -367K | -166K | - |
| Net Income | -890K | -828K | -863K | -725K | -692K | -953K | -949K | -672K | -729K | -515K | - |
| EPS | -0.02 | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | - |
| Balance Sheet | |||||||||||
| Total Assets | 197K | 218K | 166K | 101K | 85.4K | 142K | 219K | 469K | 449K | 396K | - |
| Total Liabilities | 3.13M | 3.96M | 4.63M | 4.46M | 5.08M | 5.76M | 6.70M | 7.87M | 8.83M | 8.33M | - |
| Shareholders' Equity | -2.93M | -3.74M | -4.46M | -4.36M | -5.00M | -5.62M | -6.48M | -7.40M | -8.38M | -7.94M | - |
| Cash & Short-term Investments | 48.4K | 74.4K | 38.3K | 6.56K | 7.46K | 6.86K | 5.59K | 202K | 37.0K | 4.85K | - |
| Total Debt | 2.62M | 3.45M | 3.50M | 3.08M | 3.77M | 4.33M | 4.92M | 4.74M | 6.89M | 6.81M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -605K | -732K | -820K | -372K | -558K | -832K | -743K | 647K | -846K | -735K | - |
| Capital Expenditure | 8.17K | 8.79K | 32.3K | 1.70K | 453.00 | 64.4K | 18.6K | 30.7K | 51.5K | 0.00 | - |
| Free Cash Flow | -613K | -741K | -853K | -373K | -558K | -897K | -761K | 616K | -897K | -735K | - |
| Ratios | |||||||||||
| ROA | -451.5% | -380.4% | -520.3% | -719.6% | -809.4% | -669.4% | -434.2% | -143.2% | -162.6% | -130.3% | - |
| Net Profit Margin | - | - | - | - | - | - | -8,139.5% | -543.7% | -426.1% | -190.2% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Advanced Biomedical Technologies Inc dividends
Advanced Biomedical Technologies Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 10:1 on Mar 13, 2009.
Who owns Advanced Biomedical Technologies Inc
- Insiders 3.31%
- Institutions 0.00%
- Public & others 96.69%
- Shares outstanding 70.9M
- Free float 68.2M
Advanced Biomedical Technologies Inc company profile
- Company name
- Advanced Biomedical Technologies Inc
- Ticker
- ABMT.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 17
- Fiscal year end
- October
- Address
- 200 Park Avenue, New York, NY, United States, 10166
- Phone
- 718 766 7898
- Website
- abtlafleur.com
About Advanced Biomedical Technologies Inc
Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.
Advanced Biomedical Technologies Inc management
6- Ms. Hui WangCEO, Controller & Director · born 1970
- Mr. Chi Ming YuPresident, Treasurer, Compliance Officer & Director · born 1974
- Mr. Kai GuiSecretary, CFO, COO & Director · born 1970
- Prof. Puyi Sheng M.D., Ph.D.Chief Medical Officer · born 1968
- Prof. Shangli Liu M.D., Ph.D.Chairman of Scientific Board & Chief Medical Advisor of Greater China
- Dr. John Thomas Lynch Jr.Chief Officer of Dental Technologies